An Update on the Benefits and Risks of Rosuvastatin Therapy

References

• . Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf. 2011;10(6):969–986
   PubMed Web of Science ®Google Scholar
• . Baigent C, Keech A, Kearney PM, . Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9494):1267–1278. Errata in: Lancet. 2008;371(9630):2084; Lancet. 2005;366(9494):1358
   PubMed Web of Science ®Google Scholar
• . Faergeman O, Hill L, Windler E, . ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when forcetitrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219–228
   PubMed Web of Science ®Google Scholar
• . Schuster H, Fox JC. Investigating cardiovascular risk reduction—the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother. 2004;5(5):1187–1200
   PubMed Web of Science ®Google Scholar
• . Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013
   Google Scholar
• . Lipitor [package insert]. New York, NY: Pfizer Inc; 2012
   Google Scholar
• . Lescol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012
   Google Scholar
• . Zocor [package insert]. Whitehouse Station, NJ: Merck and Co, Inc.; 2012
   Google Scholar
• . Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012
   Google Scholar
• . Sattar N, Preiss D. Murray HM, . Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375(9716):735–742
   PubMed Web of Science ®Google Scholar
• . Boekholdt SM, Arsenault BJ, Mora S, . Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. A meta-analysis. JAMA. 2012;307(12):1302–1309. Errata in: JAMA. 2012;307(16):1694; JAMA. 2012;307(18):1915
   Google Scholar
• . Stone NJ, Robinson J, Lichtenstein AH, . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force of Practice Guidelines [published online ahead of print November 12, 2013]. Circulation. No doi available
   Google Scholar
• . Ridker PM, Danielson E, Fonseca FA, ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207
   PubMed Web of Science ®Google Scholar
• . ; Expert Dyslipidemia PanelGrundy SM. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7:561–565
   PubMed Web of Science ®Google Scholar
• . Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2(3):279–285
   PubMed Web of Science ®Google Scholar
• . Alberton M, Wu P, Druyts E, Briel M, Mills EJ. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM. 2012;105(2):145–157
   PubMed Web of Science ®Google Scholar
• . Ray KK, Seshasai SR, Erqou S, . Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–1031
   PubMedGoogle Scholar
• . Olyaei A, Greer E, Santos RD, Rueda J. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clin J Am Soc Nephrol. 2011;6(3):664–678
   PubMed Web of Science ®Google Scholar
• . Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–1273
   PubMed Web of Science ®Google Scholar
• . Geluk CA, Asselbergs FW, Hillege HL, . Impact of statins in micro-albuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Hear J. 2005;26(13):1314–1320
   PubMed Web of Science ®Google Scholar
• . Fellstrom BG, Jardine AG, Schmieder RE, . AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407
   PubMed Web of Science ®Google Scholar
• . Wanner C, Krane V, März W, . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238–248
   PubMed Web of Science ®Google Scholar
• . Mosca L, Benjamin EJ, Berra K, . Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–1262. Erratum in: Circulation. 2011;124(16):e427
   Google Scholar
• . Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–1077
   PubMed Web of Science ®Google Scholar
• . Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–582
   PubMed Web of Science ®Google Scholar
• . Albert MA, Glynn RJ, Fonseca FA, . Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J. 2011;162(1):106–114.e2
   PubMed Web of Science ®Google Scholar
• . Danesh J, Wheeler JG, Hirschfield GM, . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–1397
   PubMed Web of Science ®Google Scholar
• . Danesh J, Whincup P, Walker M, . Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ. 2000;321(7255):199–204
   PubMed Web of Science ®Google Scholar
• . Shah T, Newcombe P, Smeeth L, . Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet. 2010;3(5):436–444
   PubMedGoogle Scholar
• . Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–496
   PubMed Web of Science ®Google Scholar
• . , Cholesterol Treatment Trialists' CollaborationBaigent C, Blackwell L, Emberson J, . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681
   PubMed Web of Science ®Google Scholar
• . Mills EJ, O'Regan C, Eyawo O, . Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40,000 patients. Eur Heart J. 2011;32(11):1409–1415
   PubMed Web of Science ®Google Scholar
• . Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76
   PubMed Web of Science ®Google Scholar
• . Palmer MK, Nicholles SJ, Lundman P, Barter PJ, Karlson BW. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur J Prev Cardiol. 2013;20(6):1080–1087
   PubMed Web of Science ®Google Scholar
• . Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110( 1 Suppl):3A–14A
   PubMed Web of Science ®Google Scholar
• . Crouse JR III, Raichlen JS, Riley WA, . METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007;297(12):1344–1353
   PubMed Web of Science ®Google Scholar
• . Nissen SE, Nicholls SJ, Sipahi I, . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556–1565
   PubMed Web of Science ®Google Scholar
• . Takayama T, Hiro T, Yamagishi M, ; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease. Multicenter Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Circ J. 2009;73(11):2110–2117
   PubMed Web of Science ®Google Scholar
• . Daida H, Takayama T, Hiro T, . COSMOS Investigators. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol. 2012;11:87
   PubMed Web of Science ®Google Scholar
• . Nicholls SJ, Ballantyne CM, Barter PJ, . Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087
   PubMed Web of Science ®Google Scholar
• . Kini AS, Baber U, Kovacic JC, . Changes in the plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21–29
   PubMed Web of Science ®Google Scholar
• . Yamazaki T, Nohara R, Daida H, . Justification For Atherosclerosis Regression Treatment (JART) Investigators. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J. 2013;54:33–39
   PubMed Web of Science ®Google Scholar
• . Nohara R, Daida H, Hata M, . Justification For Atherosclerosis Regression Treatment (JART) Investigators. Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness: Justification for Atherosclerosis Regression Treatment (JART) extension study. Circ J. 2013;77(6):1526–1533
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services, US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed September 24, 2013
   Google Scholar
• . Cohen DE, Anania FA, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C–81C
   PubMed Web of Science ®Google Scholar
• . McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C
   PubMed Web of Science ®Google Scholar
• . Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549–557
   PubMed Web of Science ®Google Scholar
• . Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009; 29(7):800–811
   PubMed Web of Science ®Google Scholar
• . , Cholesterol Treatment Trialists' CollaboratorsKearney PM, Blackwell L, Collins R, . Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125
   PubMed Web of Science ®Google Scholar
• . Preiss D, Seshasai SR, Welsh P, . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564
   PubMed Web of Science ®Google Scholar
• . Culver AL, Ockene IS, Balasubramanian R, . Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144–152
   PubMed Web of Science ®Google Scholar
• . Thongtang N, Ai M, Otokozawa S, . Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107(3):387–392
   PubMed Web of Science ®Google Scholar
• . Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes—the CORALL study. Diabet Med. 2012;29(5):628–631
   PubMed Web of Science ®Google Scholar
• . Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis. 2012;22(9):697–703
   PubMed Web of Science ®Google Scholar
• . Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87(1):98–107
   PubMed Web of Science ®Google Scholar
• . Abbas A, Milles J, Ramachandran S. Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dys-lipidaemia. Clin Med Insights Endocrinol Diabetes. 2012;5:13–30
   PubMedGoogle Scholar
• . Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75(4):1118–1124
   PubMed Web of Science ®Google Scholar
• . Ma T, Tien L, Fang CL, . Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–1983
   PubMed Web of Science ®Google Scholar
• . Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342–347
   PubMed Web of Science ®Google Scholar
• . Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571
   PubMed Web of Science ®Google Scholar
• . Whayne TF Jr. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators. Angiology. 2011;62(5):415–421
   PubMed Web of Science ®Google Scholar
• . Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011;6(12):e28124
   PubMed Web of Science ®Google Scholar
• . Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012;159(3):169–176
   PubMed Web of Science ®Google Scholar
• . García Rodríguez LA, Herings R, Johansson S. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins. Pharmacoepidemiol Drug Saf. 2010;19(12):1218–1224
   PubMed Web of Science ®Google Scholar
• . Stein EA, Vidt DG, Shepherd J, Cain VA, Anzalone D, Cressman MD. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis. 2012;221(2):471–477
   PubMed Web of Science ®Google Scholar
• . Wu Y, Wang Y, An C, . Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circ J. 2012;76(5):1259–1266
   PubMed Web of Science ®Google Scholar
• . Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol. 2013;167(6):2482–2489
   PubMed Web of Science ®Google Scholar
• . Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018–1028
   PubMed Web of Science ®Google Scholar
• . Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390–399
   PubMed Web of Science ®Google Scholar